Clareon Vivity Pro Extended Vision IOLs
Alcon Laboratories, LLC · Decision date Oct 30, 2026
What did the FDA approve?
The FDA recorded an approval decision on 2026-10-30 for PMA supplement P190018/S050, submitted by Alcon Laboratories, LLC under the Normal 180 Day Track. The supplement reason is a change to design, components, specifications or material, so the action covers the modified extended depth of focus intraocular lens (product code POE, ophthalmic specialty) rather than a fresh approval of the underlying system.
The approval statement lists eight Clareon Vivity Pro Extended Vision configurations: non-toric and toric versions, each with and without UV-absorbing designation, and each with and without the AutonoMe pre-loaded delivery system. The source record includes no documents, so the specific design or material changes, and any clinical data supporting them, are not described here and remain unknown.
FDA approval order statement
approval for the Clareon Vivity Pro Extended Vision IOLs, Clareon Vivity Pro Extended Vision Toric IOLs, Clareon Vivity Pro Extended Vision UV Absorbing IOL, Clareon Vivity Pro Extended Vision Toric UV Absorbing IOLs, Clareon Vivity Pro Extended Vision IOL with the AutonoMe Pre-loaded Delivery System, Clareon Vivity Pro Extended Vision Toric IOLs with the AutonoMe Pre-loaded Delivery System, Clareon Vivity Pro Extended Vision UV Absorbing IOL with the AutonoMe Pre-loaded Delivery System, and Clareon Vivity Pro Extended Vision Toric UV Absorbing IOLs with the AutonoMe Pre-loaded Delivery System
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Ophthalmic
- Decision date
- Oct 30, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P190018/S050
- Regulatory pathway
- PMA supplement
- Applicant
- Alcon Laboratories, LLC
- Product code
- POE
- Decision code
- APPR
- Decision date
- Oct 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Extended depth of focus intraocular lens.
- Applicant
- Alcon Laboratories, LLC
- Product code
- POE
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P190018. Subsequent supplements may change the device or its indications.
FDA decision timeline
P190018 · Original PMA
Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL), Clareon Toric Aspheric Hydrophobic Acrylic Intraocular Lens
P190018/S050 received
Application receipt date recorded by FDA.
P190018/S050 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P190018. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P190018
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Alcon Laboratories, LLC | PMA approval | Jan 7, 2020 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Alcon Laboratories, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6201 S. Fwy., Fort Worth, TX, 76134
Sources and methodology
- Original FDA record: P190018/S050
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records